PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AS PRIMARY TREATMENT IN ESTROGEN RECEPTOR (ER) AND HER2 POOR BREAST CANCER AND RISK OF DEVELOPING CARDIOTOXICITY OR ELDERLY PATIENTS (PT). RESULTS FROM THE PHASE II STUDY CAPRICE

M. Gil1, M. Bellet2, A. Llombart3, B. Ojeda4, L. Manso5, C. Mesia6, E. Garcia6, N. Martinez6, M. Mele6, S. Morales6, A. Fernandez Ortega7 & J. Baselga7


Current affiliations: A. Llombart H. Arnu de Vizcaya, Valencia & J. Baselga, Massachusetts General H. Boston

3rd Annual San Antonio Breast Cancer Symposium

Abstract

**Background:**
- Among triple-negative pt (N=48) pCR was 33.3%.
- Paclitaxel 80 mg/m² every w for 2 were administered every 4 weeks (w) for 4 cycles followed by PTX 80 mg/m² every 2 thereafter. The primary endpoint was pCR. Secondary endpoints included: cardiac safety, radiological response rate (RRR), breast-conserving surgery (BCS) rate, toxicity and overall survival at 5 years.

**Results:**
- pCR in Breast & Axilla
- Breast Conserving Surgery rate (BCS) rate
- Toxicity
- 5 years Overall Survival

**Conclusions:**
- Mean baseline LVEF: 66.6 (52-86) • After 16w: 66.7 (51-88) • After 28w: 62.2 (48-75) • After 40w: 64.7 (50-74)
- Two of seven T4d pt (28.7%) achieved pCR. One was excluded because of metastatic disease at baseline. A SEER study demonstrated a significantly higher incidence of Congestive Heart Failure (CHF) with DX (13).

**References**